Back to results
US 10,478,494 B2Granted
FGFR/PD-1 combination therapy for the treatment of cancer
AssigneeAstex Therapeutics Limited
InventorsJayaprakash Karkera, Suso Jesus Platero, Raluca Verona, Matthew V. Lorenzi
Life of this patent
Estimating the term…
Abstract
Provided herein are combination therapies for the treatment of cancer. In particular, the disclosed methods are directed to treatment of cancer in a patient comprising administering an antibody that blocks the interaction between PD-1 and PD-L1 and an FGFR inhibitor, wherein the antibody that blocks the interaction between PD-1 and PD-L1 and the FGFR inhibitor are administered if one or more FGFR variants are present in a biological sample from the patient.
Claims17
A method of treating cancer in a patient comprising:
- administering to the patient a pharmaceutically effective amount of an antibody that blocks the interaction between PD-1 and PD-L1;
- monitoring the efficacy of the antibody;
- and
- if the antibody is not efficacious,
- evaluating a biological sample from the patient for a presence of one or more FGFR variants, wherein the one or more FGFR variants comprise an FGFR fusion gene, and wherein the FGFR fusion gene is FGFR2:AFF3;
- FGFR2:BICC1;
- FGFR2:CASP7;
- FGFR2:CCDC6;
- FGFR2:OFD1;
- FGFR3:BAIAP2L1;
- FGFR3:TACC3-Intron;
- FGFR3:TACC3V1;
- FGFR3:TACC3V3;
- or a combination thereof;
- and
- administering to the patient a pharmaceutically effective amount of an FGFR inhibitor if the one or more FGFR variants are present in the sample, wherein the FGFR inhibitor is the compound of formula (I):
- or a pharmaceutically acceptable salt thereof.
14 more elements
Dependencies are inferred from the claim text.